Citation

Crippa JAS, Zuardi AW, Hallak JEC, Miyazawa B, Bernardo SA, Donaduzzi CM, Guzzi S, Favreto WAJ, Campos A, Queiroz MEC, Guimarães FS, da Rosa Zimmermann PM, Rechia LM, Jose Tondo Filho V, Brum Junior L. Cannabis Cannabinoid Res. 2020; 5(1): 89-98.

Affiliation

Prati Donaduzzi & Cia Ltda, Toledo, Brazil.

Copyright

(Copyright © 2020, Mary Ann Liebert Publishers)

DOI

10.1089/can.2019.0024

PMID

32322680

PMCID

PMC7173681

Abstract

Introduction: Recent studies have suggested that cannabidiol (CBD) could interconvert into Delta-8- and Delta-9- tetrahydrocannabinol. Materials and Methods: Thus, we tested the plasma samples of 120 healthy human subjects (60 male and 60 female), 60 in fasting and the other 60 under normal feeding conditions after acute administration of an oral solution containing CBD 300 mg. To do this, we developed a bioanalytical method to determine CBD and the presence of THC in plasma samples by Ultra-High Performance Liquid Chromatography Coupled to Tandem Mass Spectrometry. Results: The results showed that THC was not detected in plasma after the administration of CBD, and those study participants did not present psychotomimetic effects. Conclusions: The findings presented here are consistent with previous evidence suggesting that the oral administration of CBD in a corn oil formulation is a safe route for the administration of the active substance without bioconversion to THC in humans.

Copyright 2020, Mary Ann Liebert, Inc., publishers.

Language: en

Keywords

UHPLC-ESI-MS/MS; cannabidiol; delta-8-tetrahydrocannabinol; delta-9-tetrahydrocannabinol; interconversion; pharmacokinetics; protein precipitation